A Study of IMO-2125 in Combination with Ipilimumab vs Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Study of IMO-2125 in Combination with Ipilimumab vs Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Trial Category:
Melanoma
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
